Adherence to Growth Hormone Therapy: Results of a Multicenter Study

Basit Öğe Kaydı
dc.contributor.authorAydın, Banu Küçükemre
dc.contributor.authorAycan, Zehra
dc.contributor.authorSıklar, Zeynep
dc.contributor.authorBerberoğlu, Merih
dc.contributor.authorÖcal, Gönül
dc.contributor.authorÇetinkaya, Semra
dc.contributor.authorDarendeliler, Feyza
dc.date.accessioned2020-06-25T18:12:31Z
dc.date.available2020-06-25T18:12:31Z
dc.date.issued2014
dc.departmentKırıkkale Üniversitesi
dc.descriptionsiklar, zeynep/0000-0003-0921-2694; berberoglu, merih/0000-0003-3102-0242; Peltek Kendirci, Havva Nur/0000-0001-7398-765X
dc.description.abstractObjective: To evaluate the adherence to growth hormone (GH) therapy and identify the influencing factors and outcomes in children. Methods: A total of 217 GH-naive patients in 6 pediatric endocrinology clinics were enrolled in the study. Structured questionnaires were filled out and patients were evaluated at the initiation and 3rd, 6th, and 12th months of therapy. Patients were categorized into 4 adherence segments based on percentage of doses omitted at each evaluation period, classified as excellent if 0%, good if 5%, fair if 5 to 10%, and poor if > 10%. Results: There was a decrement in adherence to GH therapy during the study period (P = .006). Patients who showed excellent and good adherence to therapy had better growth velocity and growth velocity standard deviation scores (SDSs) (P = .014 and P = .015, respectively). A negative correlation between growth velocity SDS and number of missed injections was also observed (r = -.412; P = .007). A positive correlation between delta insulin-like growth factor-1 (IGF-1) SDS and growth velocity was demonstrated (r = .239; P = .042). IGF-1 levels were significantly higher in patients who showed excellent and good adherence to therapy (P = .01). Adherence was better in boys than in girls (P = .035), but adherence rates were not associated with age, cause of GH treatment, socioeconomic status, person who administered the injections, type of injection device, or GH product. Conclusion: Poor adherence to GH therapy was common in our group of patients and was one of the factors underlying suboptimal growth during therapy. Before considering other problems that can affect growth, clinicians should confirm good adherence to therapy.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.4158/EP13194.OR
dc.identifier.endpage51en_US
dc.identifier.issn1530-891X
dc.identifier.issn1934-2403
dc.identifier.issue1en_US
dc.identifier.pmid24013997
dc.identifier.scopus2-s2.0-84892750289
dc.identifier.scopusqualityQ1
dc.identifier.startpage46en_US
dc.identifier.urihttps://doi.org/10.4158/EP13194.OR
dc.identifier.urihttps://hdl.handle.net/20.500.12587/5949
dc.identifier.volume20en_US
dc.identifier.wosWOS:000329913500012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAmer Assoc Clinical Endocrinologistsen_US
dc.relation.ispartofEndocrine Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAdherence to Growth Hormone Therapy: Results of a Multicenter Studyen_US
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu